US equities
|
MU
$931.24
▲+0.00%
TSLA
$362.44
▲+0.00%
AAPL
$342.00
▲+0.00%
SPCX
$148.62
▲+0.00%
NVDA
$217.23
▲+0.00%
SNDK
$1,394.83
▲+0.00%
SKHY
$146.11
▲+0.00%
AMD
$562.23
▲+0.00%
MU
$931.24
▲+0.00%
TSLA
$362.44
▲+0.00%
AAPL
$342.00
▲+0.00%
SPCX
$148.62
▲+0.00%
NVDA
$217.23
▲+0.00%
SNDK
$1,394.83
▲+0.00%
SKHY
$146.11
▲+0.00%
AMD
$562.23
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Entera Bio Ltd. - Ordinary Shares
(NQ:
ENTX
)
2.770
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Entera Bio Ltd. - Ordinary Shares
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
October 13, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
October 08, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
October 06, 2026
Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies
From
Entera Bio Ltd.
Via
GlobeNewswire
Correction: Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
August 18, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Announces Second Quarter 2026 Financial Results and Business Updates
August 07, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
August 04, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 31, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
July 27, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
June 22, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
June 16, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
June 15, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 08, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
April 14, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
April 02, 2026
From
Entera Bio Ltd.
Via
GlobeNewswire
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
October 20, 2025
Via
AB Newswire
Could Oral Osteoporosis Treatment Become the Next GLP-1-Style Blockbuster?
October 08, 2025
Via
AB Newswire
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
August 22, 2025
Via
AB Newswire
